iSpecimen (ISPC) investor relations material

Company overview and business model

• Operates a technology-driven online marketplace connecting life science researchers with healthcare providers for the procurement of human biospecimens and associated data, streamlining a fragmented supply chain.

• Revenue is generated by sourcing specimens from healthcare providers and distributing them to research clients, with a flexible revenue-sharing model for suppliers.

• The platform supports both remnant and research-use-only specimens, including biofluids, tissues, and hematopoietic stem and immune cells, with a global supply network spanning 14 countries.

• Customers include biopharmaceutical companies, diagnostic firms, and government/academic institutions, with over 218,000 specimens distributed to 23 countries as of December 31, 2025.

• The company does not charge platform usage fees to customers or suppliers, focusing on transaction-based revenue.

Financial performance and metrics

• Remnant biofluids contributed 11% of revenue in 2024 and 23% in 2025; research-use-only biofluids contributed 49% in 2024 and 56% in 2025.

• Research-use-only tissue accounted for 39% of revenue in 2024 and 18% in 2025; research-use-only hematopoietic stem and immune cells made up 1% in 2024 and 3% in 2025.

• One customer accounted for 20% of total revenue in 2025, and another for 29% in 2024, indicating revenue concentration risk.

• Stockholders' equity was $1.67 million as of March 31, 2025, rising to $3.07 million by September 30, 2025, regaining Nasdaq compliance.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive nominal proceeds (approx. $40) from cash exercise of pre-funded warrants, to be used for working capital and general corporate purposes.

• Net proceeds from the May 2026 Private Placement (approx. $2.5 million) are intended for working capital, including up to $900,000 for marketing expenses.